News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
JP Morgan JPM2023: Breakthroughs await, but so do roadblocks Editor-in-chief Jonah Comstock lays out a few of the most potent threads he heard in the conference centres, hotel rooms, and rain-soaked Lyfts of San Francisco.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.